Tatva Chintan Pharma Chem LimitedQ2 FY27 Results & Financial Update
Tatva Chintan Pharma Chem Limited: Q2 FY27 consolidated results and company financials – revenue ₹217.32 Cr, PAT ₹21.45 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Tatva Chintan Pharma Chem price & chart
Market price₹1,703.70
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Tatva Chintan Pharma Chem Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Tatva Chintan Pharma Chem Limited delivered a record financial performance in Q2 FY27, achieving its highest-ever quarterly turnover of INR 217.32 crore, representing a 30.09% sequential expansion over the INR 167.06 crore reported in Q1 FY27.
Bottom-line profitability expanded in tandem with top-line growth. Profit Before Tax (PBT) for the quarter rose by 37.08% sequentially to INR 28.94 crore from INR 21.11 crore in the preceding quarter, while Profit After Tax (PAT) advanced by 34.23% sequentially to INR 21.45 crore compared to INR 15.98 crore.
Basic Earnings Per Share (EPS) for Q2 FY27 stood at INR 9.17, compared to INR 6.83 recorded in Q1 FY27, reflecting the higher earnings realization during the period under review.
Management noted that the record turnover was underpinned by robust commercial traction across diversified portfolios, particularly within Structure Directing Agents (SDA) driven by EURO 7 emission standard implementations, alongside positive contributions from newer initiatives in energy storage and agro/pharma intermediates.
Despite the strong revenue momentum and positive operating leverage—evidenced by reductions in employee benefit expenses and other expenses—EBITDA levels were temporarily constrained by external pressures, specifically erratic short supplies of key solvents leading to 60%-100% price surges, and a more than 100% spike in global freight rates particularly affecting US and Europe trade routes.
Management stated that these cost headwinds are temporary and that gradual reversals are already visible, with expectations of normalization during the third quarter of FY27.
01 · Business model
What does Tatva Chintan Pharma Chem do?
Tatva Chintan Pharma Chem Limited is an integrated specialty chemical company established in 1996 by first-generation entrepreneur engineers, manufacturing products across four main categories: Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), and Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC).
The company operates manufacturing facilities located at Ankleshwar and Dahej SEZ in Gujarat, equipped with a combined reactor capacity of 791 KL and 39 assembly lines as of March 31, 2026. It also maintains a dedicated DSIR-recognized R&D center in Vadodara, Gujarat.
Tatva Chintan is a pioneer in green chemistry processes such as electrolysis and continuous flow chemistry, generating high-purity products with low process mass intensity. Its customer base spans over 30 countries, including the USA, UK, China, Germany, Japan, and South Africa, supported by overseas subsidiaries in the USA and Netherlands and warehousing facilities in Amsterdam and Savanna.
02 · Historical context
What shaped the business before this quarter
Established in 1996 by first-generation entrepreneur engineers, the company commenced commercial manufacturing of SDAs in 2011 and expanded operations by setting up its Dahej SEZ manufacturing facility in 2017.
The company began R&D into electrolysis in 2007, achieving commercial approval for electrolysis-produced products in 2015, and initiated R&D into continuous flow chemistry in 2018.
Tatva Chintan completed its initial public offering and listed on BSE and NSE in July 2021, later raising INR 200 crore through a Qualified Institutional Placement in August 2023.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹217.32 Cr | ₹167.06 Cr |
| Total income | ₹219.07 Cr | ₹169.84 Cr |
| Profit before tax | ₹28.94 Cr | ₹21.11 Cr |
| Profit after tax | ₹21.45 Cr | ₹15.98 Cr |
| EPS | ₹9.17 | ₹6.83 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 9.9% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 13.3% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹1.75 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Structure Directing Agents (SDA) contributed 45% of operating revenue in Q2 FY27 (up from 41% in FY26), bolstered by strong demand arising from the implementation of EURO 7 emission standards globally.
Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) contributed 30% of Q2 FY27 revenue, while Phase Transfer Catalysts (PTC) accounted for 21%, supported by recurring demand from diverse chemical industries.
What drove margins
While the company achieved positive operating leverage through reductions in employee benefit expenses and other expenses relative to revenue growth, overall raw material costs were elevated by short supplies and 60%-100% price spikes in major solvents.
Margins were further constrained during the quarter by sharp increases in global freight rates exceeding 100% on specific US and Europe export routes, which management expects to normalize in Q3 FY27.
05 · Demand, customers & order book
Where demand is coming from
The company maintains long-standing relationships with marquee global customers across pharmaceuticals, agrochemicals, and specialty sectors, including Merck, Laurus Labs, Divi's Laboratories, Atul, SRF, Bayer, and Otsuka.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Maintains a leading position as the second largest manufacturer of SDAs for zeolites globally and the largest commercial supplier in India, benefiting from stricter emission norms and EURO 7 implementation.
Energy storage applications continue to expand, with hybrid-battery applications progressing toward commercialisation and additional electrolyte salt products scaling up for super-capacitor batteries.
All five products in the semiconductor chemicals development portfolio are progressing well through development, validation, and customer qualification stages.
Geography and market mix
Exports accounted for 75% of revenue in FY26, with products shipped to over 30 countries including the USA, UK, China, Germany, Japan, and South Africa.
Operations are supported by overseas subsidiaries (Tatva Chintan USA Inc. and Tatva Chintan Europe BV) and warehousing facilities located in Amsterdam, Netherlands, and Savanna, USA.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
The new greenfield project is progressing in line with schedule to provide additional manufacturing capacity for organic expansion and the commercialisation of new pipeline molecules.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Continued strategic emphasis on proprietary green chemistry processes, including electrolysis and continuous flow chemistry, designed to minimize waste, lower treatment costs, and achieve low process mass intensity.
09 · Reported developments
What changed operationally
Achieved the highest-ever quarterly turnover of INR 217.32 crore in Q2 FY27, reflecting robust demand across core specialty chemical portfolios.
Recently commercialized agro products are performing well, and newly introduced pharma products have begun contributing to revenue streams.
10 · Management guidance & targets
What management is targeting from here
Management expects revenue growth momentum to continue over coming quarters and anticipates that EBITDA margins will resume their healthy trajectory as solvent and freight cost headwinds normalize during Q3 FY27.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Sustainability and ESG Recognition
Tatva Chintan's sustainability performance, as monitored by EcoVadis and TfS, continues to score above industry averages, supported by zero liquid effluent discharge status at its Ankleshwar facility.
12 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations expanded by 30.09% from INR 167.06 crore in Q1 FY27 to INR 217.32 crore in Q2 FY27.
13 · Key Q&A
The quarter, answered directly
What does Tatva Chintan Pharma Chem do?
Tatva Chintan Pharma Chem Limited is an integrated specialty chemical company established in 1996 by first-generation entrepreneur engineers, manufacturing products across four main categories: Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), and Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC).
What is the clearest takeaway from Q2 FY27?
Tatva Chintan Pharma Chem Limited delivered a record financial performance in Q2 FY27, achieving its highest-ever quarterly turnover of INR 217.32 crore, representing a 30.09% sequential expansion over the INR 167.06 crore reported in Q1 FY27.
What drove revenue or demand?
Structure Directing Agents (SDA) contributed 45% of operating revenue in Q2 FY27 (up from 41% in FY26), bolstered by strong demand arising from the implementation of EURO 7 emission standards globally.
What mattered most for margins or profitability?
While the company achieved positive operating leverage through reductions in employee benefit expenses and other expenses relative to revenue growth, overall raw material costs were elevated by short supplies and 60%-100% price spikes in major solvents.
What changed operationally beyond the headline numbers?
The new greenfield project is progressing in line with schedule to provide additional manufacturing capacity for organic expansion and the commercialisation of new pipeline molecules.
What is management guiding or targeting from here?
Management expects revenue growth momentum to continue over coming quarters and anticipates that EBITDA margins will resume their healthy trajectory as solvent and freight cost headwinds normalize during Q3 FY27.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Solvent and Freight Normalization: Monitor Q3 FY27 financial results for the anticipated normalization of solvent prices and global freight rates to assess EBITDA margin recovery.
- 02
Greenfield Project Progress: Track construction milestones and commissioning updates regarding the new greenfield manufacturing facility.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.